<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911023-0021</DOCNO><DOCID>911023-0021.</DOCID><HL>   Technology:   Repligen to Reacquire   From Merck Rights   To Certain Antibodies</HL><DATE>10/23/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   MRK RGEN</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>MASSACHUSETTS (MA)NEW JERSEY (NJ)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   CAMBRIDGE, Mass. -- Repligen Corp. said it is reacquiringfrom Merck andamp; Co. the rights to certain monoclonal antibodiesthat the two companies have been developing as a potentialHIV anti-infective.   Terms of the reaquisition haven't been completed, Repligensaid. But the biotechnology and health-care concern plans tocontinue development and funding of this program on its ownfrom cash reserves of more than $50 million.</LP><TEXT>   Repligen's stock price has risen steadily in nationalover-the-counter trading in the past few days. In late OTCtrading yesterday, Repligen shares soared $5.25 each, to $29.On Friday, the company announced that it had conducted twoanimal studies with Merck that indicated it may be feasibleto develop an anti-infective against acquired immunedeficiency syndrome infections in humans.   Repligen said its clinical emphasis with the monoclonalantibodies will be in the area of HIV therapy. Repligen saidMerck plans to license separately other antibodies as apotential HIV anti-infective for postexposure prophylaxis.   &quot;Reacquiring these rights will allow Repligen toaggressively pursue development of our lead therapeuticmonoclonal antibody product,&quot; said Sandford D. Smith,Repligen president and chief executive officer. The companysaid it signed the initial development agreement in 1989.   He added that Repligen's initial clinical strategy will beto evaluate the product candidate in AIDS patients. Otherpossible clinical applications include prevention ofmother-neonate transmission of HIV and post-exposureinfection, Mr. Smith said.   Repligen said it will continue to pursue the developmentof an AIDS vaccine with Merck under a separate agreement thatbegan in 1987.</TEXT></DOC>